Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Not pending/lapsed |
21 | DE file number | DAKZ | 60 2011 072 317.0 |
96 | EP file number | EAKZ | 19 21 8636.9 |
97 | EP publication number | EPN | 3663399 |
54 | Designation/title | TI | MODIFIZIERTE FAKTOR-IX-POLYPEPTIDE UND IHRE VERWENDUNGEN |
51 | IPC main class | ICM (ICMV) | C12N 9/64 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | C12N 15/55 (2006.01), A61K 38/43 (2006.01) |
22 | DE application date | DAT | Nov 3, 2011 |
96 | EP application date | EAT | Nov 3, 2011 |
43 | Date of first publication | OT | Jun 10, 2020 |
| Date of publication of grant | PET | Dec 22, 2021 |
71/73 | Applicant/owner | INH | GC Biopharma Corp., Yongin-si, Gyeonggi-do, KR |
72 | Inventor | IN | MADISON, Edwin L, San Francisco, CA 94121, US; THANOS, Christopher, Tiburon, CA 94920, US; BLOUSE, Grant Ellsworth, Burlingame, CA 94010, US |
| Address for service | | Weickmann & Weickmann Patent- und Rechtsanwälte PartmbB, 81679 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 45629810 P Nov 3, 2010
|
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003663399A1 Searchable text:
EP000003663399A1 Original document:
EP000003663399B1 Searchable text:
EP000003663399B1 |
43 | Date of first publication | EVT | Jun 10, 2020 |
| Date of the first transfer into DPMAregister | EREGT | Jun 10, 2020 |
| Date of the (most recent) update in DPMAregister | REGT | Jul 20, 2025 (Show all update days)(Hide all update days)- Jul 20, 2025
- Status: changed
- Due date: deleted
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 22.12.2021: new
- Procedures: Administrative procedure, Application deemed withdrawn due to non-payment of annual fee, 03.06.2025: new
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 22.12.2021: deleted
- Oct 10, 2024
- St.36: changed (technical change)
- Jun 10, 2020
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 6)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Apr 13, 2023 |
| Issue number | HN | 21 |
| Year | PJ | 2023 |
| Publication date | VT | May 25, 2023 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | GC Biopharma Corp., Yongin-si, Gyeonggi-do, KR |
71/73 | Previous applicant/owner | INHF | Catalyst Biosciences, Inc., South San Francisco, CA, US |
| Date of update of the procedure | REGT | May 25, 2023 |